The clinical role of antibody-based therapy currently approved for AML treatment is limited to antibody-drug conjugates (ADCs), wherein an innate immune response is elicited towards a myeloid-specific antigen, such as CD33-binding gemtuzumab ozogamicin [5,48,49]. This evidence concerns the gene CD33 and acute myeloid leukemia.